|
1
|
Vargas-Hernández VM, Moreno-Eutimio MA,
Acosta-Altamirano G and Vargas-Aguilar VM: Management of recurrent
epithelial ovarian cancer. Gland Surg. 3:198–202. 2014.PubMed/NCBI
|
|
2
|
Xu L, Cai J, Yang Q, Ding H, Wu L, Li T
and Wang Z: Prognostic significance of several biomarkers in
epithelial ovarian cancer: A meta-analysis of published studies. J
Cancer Res Clin Oncol. 139:1257–1277. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yeh YM, Chuang CM, Chao KC and Wang LH:
MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis
by targeting SOX4 and HIF-1α. Int J Cancer. 133:867–878. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang L, Lv W and Zhao X: CD24 as a
molecular marker in ovarian cancer: A literature review. Cancer
Transl Med. 2:29–32. 2016. View Article : Google Scholar
|
|
5
|
Coleman RL, Monk BJ, Sood AK and Herzog
TJ: Latest research and treatment of advanced-stage epithelial
ovarian cancer. Nat Rev Clin Oncol. 10:211–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Minig L, Otaño L, Diaz-Padilla I, Gallego
R Alvarez, Patrono MG and de Bernabé J Valero: Therapeutic
management of epithelial ovarian cancer during pregnancy. Clin
Transl Oncol. 15:259–264. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hata A and Lieberman J: Dysregulation of
microRNA biogenesis and gene silencing in cancer. Sci Signal.
8:re32015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shen J and Hung MC: Signaling-mediated
regulation of MicroRNA processing. Cancer Res. 75:783–791. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zaman MS, Maher DM, Khan S, Jaggi M and
Chauhan SC: Current status and implications of microRNAs in ovarian
cancer diagnosis and therapy. J Ovarian Res. 5:442012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mansoori B, Mohammadi A, Shirjang S and
Baradaran B: Micro-RNAs: The new potential biomarkers in cancer
diagnosis, prognosis and cancer therapy. Cell Mol Biol
(Noisy-le-grand). 61:1–10. 2015.PubMed/NCBI
|
|
12
|
Wang YQ, Guo RD, Guo RM, Sheng W and Yin
LR: MicroRNA-182 promotes cell growth, invasion, and
chemoresistance by targeting programmed cell death 4 (PDCD4) in
human ovarian carcinomas. J Cell Biochem. 114:1464–1473. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang H, Wang Q, Zhao Q and Di W: MiR-124
inhibits the migration and invasion of ovarian cancer cells by
targeting SphK1. J Ovarian Res. 6:842013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu H, Xiao Z, Wang K, Liu W and Hao Q:
MiR-145 is downregulated in human ovarian cancer and modulates cell
growth and invasion by targeting p70S6K1 and MUC1. Biochem Biophys
Res Commun. 441:693–700. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gui T, Bai H, Zeng J, Zhong Z, Cao D, Cui
Q, Chen J, Yang J and Shen K: Tumor heterogeneity in the recurrence
of epithelial ovarian cancer demonstrated by polycomb group
proteins. Onco Targets Ther. 7:1705–1716. 2014.PubMed/NCBI
|
|
16
|
Pereira A, Pérez-Medina T, Magrina JF,
Magtibay PM, Rodríguez-Tapia A, Peregrin I, Mendizabal E and
Ortiz-Quintana L: International Federation of Gynecology and
Obstetrics staging classification for cancer of the ovary,
fallopian tube, and peritoneum: Estimation of survival in patients
with node-positive epithelial ovarian cancer. Int J Gynecol Cancer.
25:49–54. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang Q, Padi SK, Tindall DJ and Guo B:
Polycomb protein EZH2 suppresses apoptosis by silencing the
proapoptotic miR-31. Cell Death Dis. 5:e14862014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Semaan A, Qazi AM, Seward S, Chamala S,
Bryant CS, Kumar S, Morris R, Steffes CP, Bouwman DL, Munkarah AR,
et al: MicroRNA-101 inhibits growth of epithelial ovarian cancer by
relieving chromatin-mediated transcriptional repression of
p21(waf1/cip1). Pharm Res. 28:3079–3090. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim TH, Song JY, Park H, Jeong JY, Kwon
AY, Heo JH, Kang H, Kim G and An HJ: miR-145, targeting
high-mobility group A2, is a powerful predictor of patient outcome
in ovarian carcinoma. Cancer Lett. 356:937–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Selth LA, Townley S, Gillis JL, Ochnik AM,
Murti K, Macfarlane RJ, Chi KN, Marshall VR, Tilley WD and Butler
LM: Discovery of circulating microRNAs associated with human
prostate cancer using a mouse model of disease. Int J Cancer.
131:652–661. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bao L, Hazari S, Mehra S, Kaushal D, Moroz
K and Dash S: Increased expression of P-glycoprotein and
doxorubicin chemoresistance of metastatic breast cancer is
regulated by miR-298. Am J Pathol. 180:2490–2503. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Han Li C and Chen Y: Targeting EZH2 for
cancer therapy: Progress and perspective. Curr Protein Pept Sci.
16:559–570. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Verma SK: Inhibition of the histone lysine
methyltransferase EZH2 for the treatment of cancer. Curr Top Med
Chem. 15:714–719. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li LY: EZH2: Novel therapeutic target for
human cancer. Biomedicine (Taipei). 4:12014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gong Y, Huo L, Liu P, Sneige N, Sun X,
Ueno NT, Lucci A, Buchholz TA, Valero V and Cristofanilli M:
Polycomb group protein EZH2 is frequently expressed in inflammatory
breast cancer and is predictive of worse clinical outcome. Cancer.
117:5476–5484. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang YA and Yu J: EZH2, an epigenetic
driver of prostate cancer. Protein Cell. 4:331–341. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li T, Cai J, Ding H, Xu L, Yang Q and Wang
Z: EZH2 participates in malignant biological behavior of epithelial
ovarian cancer through regulating the expression of BRCA1. Cancer
Biol Ther. 15:271–278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu L, Guo J, Yu L, Cai J, Gui T, Tang H,
Song L, Wang J, Han F, Yang C, et al: miR-101 regulates expression
of EZH2 and contributes to progression of and cisplatin resistance
in epithelial ovarian cancer. Tumour Biol. 35:12619–12626. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Martin TA, Ye L, Sanders AJ, Lane J and
Jiang WG: Cancer invasion and metastasis: Molecular and cellular
perspectiveMetastatic Cancer: Clinical and Biological Perspectives.
Jandial R: Madame Curie Bioscience Database. Landes Bioscience;
Austin, TX: pp. 2000–2013
|
